Response to PARP Inhibition in BARD1-Mutated Refractory Neuroblastoma

Some neuroblastomas carry disabling mutations in BARD1, a homologous recombination repair gene. A child with refractory neuroblastoma and a BARD1 mutation had a sustained response after treatment with the PARP inhibitor talazoparib.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology